Kalaris Therapeutics, Inc. (NASDAQ:KLRS) is a clinical‐stage biopharmaceutical company focused on discovering and developing novel therapies for oncology and immune‐mediated diseases. Leveraging a proprietary antibody engineering platform, the company aims to create multifunctional molecules that engage multiple targets within the tumor microenvironment. Kalaris’s lead programs are designed to enhance anti‐tumor immune responses while simultaneously inhibiting pathways that drive tumor growth and immune evasion.
The company’s pipeline includes several antibody‐based candidates targeting solid tumors and hematologic malignancies. These candidates are engineered to bind dual or tri‐specific antigens, increasing the precision of immune cell recruitment and activation. Kalaris has established preclinical collaborations with leading academic centers in North America and Europe, and is preparing to initiate its first Phase I clinical trial in patients with advanced solid tumors. In addition to oncology, the company is exploring internally discovered molecules for potential application in autoimmune and inflammatory diseases.
Founded in 2017, Kalaris Therapeutics is headquartered in San Diego, California, with research facilities in Cambridge, Massachusetts, and a European affiliate in Basel, Switzerland. The company was seeded through a series of venture financing rounds led by several life science investment groups, enabling the build‐out of its integrated discovery and development capabilities. Kalaris maintains strategic partnerships with contract research organizations and biotechnology firms to accelerate its pipeline advancement and manufacturing scale‐up.
Under the leadership of President and Chief Executive Officer Dr. Nina Patel, a veteran immunologist with over 20 years of experience in antibody‐based drug development, Kalaris is guided by an executive team combining expertise in molecular biology, translational research, and clinical operations. The Board of Directors includes industry leaders and seasoned pharma executives, ensuring strong governance as the company moves its lead candidates toward regulatory milestones and potential commercialization.
AI Generated. May Contain Errors.
Free KLRS Stock Alerts